BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Menck K, Heinrichs S, Baden C, Bleckmann A. The WNT/ROR Pathway in Cancer: From Signaling to Therapeutic Intervention. Cells 2021;10:142. [PMID: 33445713 DOI: 10.3390/cells10010142] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 30.0] [Reference Citation Analysis]
Number Citing Articles
1 John M, Ford CE. Pan-Tissue and -Cancer Analysis of ROR1 and ROR2 Transcript Variants Identify Novel Functional Significance for an Alternative Splice Variant of ROR1. Biomedicines 2022;10:2559. [PMID: 36289823 DOI: 10.3390/biomedicines10102559] [Reference Citation Analysis]
2 Flanagan DJ, Woodcock SA, Phillips C, Eagle C, Sansom OJ. Targeting ligand-dependent wnt pathway dysregulation in gastrointestinal cancers through porcupine inhibition. Pharmacology & Therapeutics 2022;238:108179. [DOI: 10.1016/j.pharmthera.2022.108179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Raivola J, Dini A, Karvonen H, Piki E, Salokas K, Niininen W, Kaleva L, Zhang K, Arjama M, Gudoityte G, Seashore-ludlow B, Varjosalo M, Kallioniemi O, Hautaniemi S, Murumägi A, Ungureanu D. Multiomics characterization implicates PTK7 in ovarian cancer EMT and cell plasticity and offers strategies for therapeutic intervention. Cell Death Dis 2022;13:714. [DOI: 10.1038/s41419-022-05161-5] [Reference Citation Analysis]
4 Peng H, Nerreter T, Mestermann K, Wachter J, Chang J, Hudecek M, Rader C. ROR1-targeting switchable CAR-T cells for cancer therapy. Oncogene 2022. [PMID: 35859167 DOI: 10.1038/s41388-022-02416-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Zhao H, Ming T, Tang S, Ren S, Yang H, Liu M, Tao Q, Xu H. Wnt signaling in colorectal cancer: pathogenic role and therapeutic target. Mol Cancer 2022;21:144. [PMID: 35836256 DOI: 10.1186/s12943-022-01616-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Paskeh MDA, Entezari M, Mirzaei S, Zabolian A, Saleki H, Naghdi MJ, Sabet S, Khoshbakht MA, Hashemi M, Hushmandi K, Sethi G, Zarrabi A, Kumar AP, Tan SC, Papadakis M, Alexiou A, Islam MA, Mostafavi E, Ashrafizadeh M. Emerging role of exosomes in cancer progression and tumor microenvironment remodeling. J Hematol Oncol 2022;15:83. [PMID: 35765040 DOI: 10.1186/s13045-022-01305-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
7 Nadanaka S, Tamura JI, Kitagawa H. Chondroitin Sulfates Control Invasiveness of the Basal-Like Breast Cancer Cell Line MDA-MB-231 Through ROR1. Front Oncol 2022;12:914838. [PMID: 35712490 DOI: 10.3389/fonc.2022.914838] [Reference Citation Analysis]
8 Martín-Medina A, Cerón-Pisa N, Martinez-Font E, Shafiek H, Obrador-Hevia A, Sauleda J, Iglesias A. TLR/WNT: A Novel Relationship in Immunomodulation of Lung Cancer. Int J Mol Sci 2022;23:6539. [PMID: 35742983 DOI: 10.3390/ijms23126539] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Yan Q, Fang X, Li C, Lan P, Guan X. Oncofetal proteins and cancer stem cells. Essays in Biochemistry 2022. [DOI: 10.1042/ebc20220025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Chu CN, Lee TKW. Targeting protein kinases in cancer stem cells. Essays Biochem 2022:EBC20220002. [PMID: 35607921 DOI: 10.1042/EBC20220002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Xie X, Lee J, Iwase T, Kai M, Ueno NT. Emerging drug targets for triple-negative breast cancer: A guided tour of the preclinical landscape. Expert Opin Ther Targets 2022. [PMID: 35574694 DOI: 10.1080/14728222.2022.2077188] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Guarino SR, Di Bello A, Palamini M, Capillo MC, Forneris F. Crystal structure of the kringle domain of human receptor tyrosine kinase-like orphan receptor 1 (hROR1). Acta Cryst Sect F 2022;78:185-192. [DOI: 10.1107/s2053230x22003855] [Reference Citation Analysis]
13 Millesi M, Ryba AS, Hainfellner JA, Roetzer T, Berghoff AS, Preusser M, Heller G, Tomasich E, Sahm F, Roessler K, Wolfsberger S. DNA Methylation Associates With Clinical Courses of Atypical Meningiomas: A Matched Case-Control Study. Front Oncol 2022;12:811729. [PMID: 35356207 DOI: 10.3389/fonc.2022.811729] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Fox SA, Vacher M, Farah CS. Transcriptomic Biomarker Signatures for Discrimination of Oral Cancer Surgical Margins. Biomolecules 2022;12:464. [DOI: 10.3390/biom12030464] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Shah K, Kazi JU. Phosphorylation-Dependent Regulation of WNT/Beta-Catenin Signaling. Front Oncol 2022;12:858782. [DOI: 10.3389/fonc.2022.858782] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Babin L, Darchen A, Robert E, Aid Z, Borry R, Soudais C, Piganeau M, De Cian A, Giovannangeli C, Bawa O, Rigaud C, Scoazec JY, Couronné L, Veleanu L, Cieslak A, Asnafi V, Sibon D, Lamant L, Meggetto F, Mercher T, Brunet E. De novo generation of the NPM-ALK fusion recapitulates the pleiotropic phenotypes of ALK+ ALCL pathogenesis and reveals the ROR2 receptor as target for tumor cells. Mol Cancer 2022;21:65. [PMID: 35246138 DOI: 10.1186/s12943-022-01520-0] [Reference Citation Analysis]
17 Castro MV, Lopez-Bergami P. Cellular and Molecular Mechanisms Implicated in the Dual Role of ROR2 in Cancer. Crit Rev Oncol Hematol 2022;:103595. [PMID: 35032666 DOI: 10.1016/j.critrevonc.2022.103595] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
18 Córdova-Bahena L, Sánchez-Álvarez AA, Ruiz-Moreno AJ, Velasco-Velázquez MA. Repositioning of Etravirine as a Potential CK1ε Inhibitor by Virtual Screening. Pharmaceuticals (Basel) 2021;15:8. [PMID: 35056065 DOI: 10.3390/ph15010008] [Reference Citation Analysis]
19 Menck K, Heinrichs S, Wlochowitz D, Sitte M, Noeding H, Janshoff A, Treiber H, Ruhwedel T, Schatlo B, von der Brelie C, Wiemann S, Pukrop T, Beißbarth T, Binder C, Bleckmann A. WNT11/ROR2 signaling is associated with tumor invasion and poor survival in breast cancer. J Exp Clin Cancer Res 2021;40:395. [PMID: 34911552 DOI: 10.1186/s13046-021-02187-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
20 John M, Ford C. Pan-tissue and -cancer analysis of ROR1 and ROR2 transcript variants identify novel functional significance for an alternative splice variant of ROR1.. [DOI: 10.1101/2021.11.24.469652] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Peng H. Perspectives on the development of antibody-drug conjugates targeting ROR1 for hematological and solid cancers. Antib Ther 2021;4:222-7. [PMID: 34805745 DOI: 10.1093/abt/tbab023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
22 Grund A, Till K, Giehl K, Borchers A. Ptk7 Is Dynamically Localized at Neural Crest Cell-Cell Contact Sites and Functions in Contact Inhibition of Locomotion. Int J Mol Sci 2021;22:9324. [PMID: 34502237 DOI: 10.3390/ijms22179324] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Yeh CF, Chan TC, Ke HL, Chen TJ, Wu LC, Lee HY, Wei YC, Wu WJ, Li CF, Li WM. Prognostic Significance of ROR2 Expression in Patients with Urothelial Carcinoma. Biomedicines 2021;9:1054. [PMID: 34440262 DOI: 10.3390/biomedicines9081054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Merikhian P, Eisavand MR, Farahmand L. Triple-negative breast cancer: understanding Wnt signaling in drug resistance. Cancer Cell Int 2021;21:419. [PMID: 34376211 DOI: 10.1186/s12935-021-02107-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 15.0] [Reference Citation Analysis]
25 Latour M, Her NG, Kesari S, Nurmemmedov E. WNT Signaling as a Therapeutic Target for Glioblastoma. Int J Mol Sci 2021;22:8428. [PMID: 34445128 DOI: 10.3390/ijms22168428] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
26 Benoit I, Brownell S, Douville RN. Predicted Cellular Interactors of the Endogenous Retrovirus-K Integrase Enzyme. Microorganisms 2021;9:1509. [PMID: 34361946 DOI: 10.3390/microorganisms9071509] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Barzaman K, Moradi-Kalbolandi S, Hosseinzadeh A, Kazemi MH, Khorramdelazad H, Safari E, Farahmand L. Breast cancer immunotherapy: Current and novel approaches. Int Immunopharmacol 2021;98:107886. [PMID: 34153663 DOI: 10.1016/j.intimp.2021.107886] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 13.0] [Reference Citation Analysis]
28 Zhao Y, Zhang D, Guo Y, Lu B, Zhao ZJ, Xu X, Chen Y. Tyrosine Kinase ROR1 as a Target for Anti-Cancer Therapies. Front Oncol 2021;11:680834. [PMID: 34123850 DOI: 10.3389/fonc.2021.680834] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
29 Bocharova EA, Kopytina NI, Slynko ЕЕ. Anti-tumour drugs of marine origin currently at various stages of clinical trials (review). Regul Mech Biosyst 2021;12:265-80. [DOI: 10.15421/022136] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]